AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25478237 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation over the left primary auditory cortex
Number of subjects: 23
Study 22441774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control
Number of subjects: 933
Study 22441774 — intervention group
Group type: COMPARATOR
Intervention: Rate-control
Number of subjects: 933
Study 20570361 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 60
Study 20570361 — intervention group
Group type: COMPARATOR
Intervention: Sub‐Tenon's anesthesia
Number of subjects: 60
Study 18716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Diepoxybutane 0.1 mug/ml
Number of subjects: 27
Study 18716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.1 microg/ml
Number of subjects: 27
Study 18716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation (300 rads)
Number of subjects: 27
Study 18716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation (400 rads)
Number of subjects: 27
Study 18716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin and rad4
Number of subjects: 27
Study 18716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean chromosomal breakage
Number of subjects: 27
Study 16622371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group intervention
Number of subjects: 213
Study 16622371 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus information on self-care (information comparison group)
Number of subjects: 213
Study 12727316 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief and unobtrusive instrument to detect simulation and exaggeration in patients with whiplash syndrome.
Number of subjects: 100
Study 10829398 — intervention group
Group type: EXPERIMENTAL
Intervention: HDBPM oscillometric sphygmomanometer
Number of subjects: 92
Study 8800586 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (40-55% HRres)
Number of subjects: 126
Study 8800586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (65-80% HRres)
Number of subjects: 126
Study 8800586 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing participation in any regular exercise
Number of subjects: 126
Study 8800586 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 126
Study 1641050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol I: 240 mg paracetamol
Number of subjects: 64
Study 1641050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol II: 500 mg paracetamol
Number of subjects: 64
Study 1641050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol III: 500 mg paracetamol plus 10 mg codeine
Number of subjects: 64
Study 6381269 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumetacin 450 mg/day (150 mg in the morning, 300 mg in the evening)
Number of subjects: 50
Study 6381269 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day (placebo in the morning, 20 mg in the evening)
Number of subjects: 50
Study 30610038 — intervention group
Group type: EXPERIMENTAL
Intervention: TMIT I (both PD‐L1‐positive tumor cells & CD8‐high TILs)
Number of subjects: 479
Study 30610038 — intervention group
Group type: EXPERIMENTAL
Intervention: TMIT III (PD‐L1‐positive tumor cells & CD8‐low TILs)
Number of subjects: 479
Study 30610038 — intervention group
Group type: EXPERIMENTAL
Intervention: PD‐L1 expression
Number of subjects: 479
Study 27215455 — intervention group
Group type: EXPERIMENTAL
Intervention: CT guided radiofrequency ablation followed by intratumoral chemotherapy (RFA-ITC)
Number of subjects: 110
Study 24758245 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/PEEP of 6 cmH2O with FIO2 1.0
Number of subjects: 30
Study 24758245 — intervention group
Group type: COMPARATOR
Intervention: No CPAP/PEEP with FIO2 1.0
Number of subjects: 30
Study 24758245 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/PEEP of 6 cmH2O with FIO2 0.8
Number of subjects: 30
Study 22102090 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 597
Study 22102090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 597
Study 20679668 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 241
Study 20679668 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 241
Study 18815843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (collaborative management by primary care-pharmacist teams)
Number of subjects: 463
Study 18815843 — intervention group
Group type: COMPARATOR
Intervention: Control (usual primary care)
Number of subjects: 463
Study 15902994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 34
Study 15902994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg/day
Number of subjects: 34
Study 15902994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12920428 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music therapy (n = 100)
Number of subjects: 198
Study 12920428 — intervention group
Group type: COMPARATOR
Intervention: No music (Control group, n = 98)
Number of subjects: 198
Study 10505693 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 (250 mg)
Number of subjects: 0
Study 10505693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8941477 — intervention group
Group type: EXPERIMENTAL
Intervention: LysB28, ProB29-human insulin analogue (lispro)
Number of subjects: 27
Study 8941477 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 27
Study 1752019 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen (N2O/O2)
Number of subjects: 10
Study 1752019 — intervention group
Group type: COMPARATOR
Intervention: Air in oxygen (N2/O2)
Number of subjects: 10
Study 6810843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin sodium, 5,000 IU/6 hr
Number of subjects: 47
Study 6810843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 47
Study 30068416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 0
Study 30068416 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 25632044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute mindful breathing
Number of subjects: 20
Study 25632044 — intervention group
Group type: COMPARATOR
Intervention: Listening (being listened to)
Number of subjects: 20
Study 23904472 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised combined resistance and aerobic exercise intervention for 6 months
Number of subjects: 40
Study 23904472 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only information about the benefits of exercise
Number of subjects: 40
Study 22484799 — intervention group
Group type: EXPERIMENTAL
Intervention: arzoxifene 20 mg/day
Number of subjects: 9354
Study 22484799 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9354
Study 20380924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic speed limit system (basic roadside, advanced roadside, advanced in-car)
Number of subjects: 46
Study 20380924 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced dynamic speed limit system
Number of subjects: 46
Study 20380924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic speed limit systems
Number of subjects: 46
Study 20380924 — intervention group
Group type: COMPARATOR
Intervention: Static speed limit system
Number of subjects: 46
Study 18771352 — intervention group
Group type: EXPERIMENTAL
Intervention: FWGE (fermented wheat germ extract)
Number of subjects: 0
Study 18771352 — intervention group
Group type: COMPARATOR
Intervention: Control (dacarbazine-based chemotherapy)
Number of subjects: 0
Study 15821654 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial line leukocyte filter (Pall LeukoGuard 6)
Number of subjects: 50
Study 15821654 — intervention group
Group type: COMPARATOR
Intervention: Control group without any filter
Number of subjects: 50
Study 15328774 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Thai passages devoid of nasal consonants
Number of subjects: 188
Study 15328774 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Thai passages with a mixture of oral and nasal consonants
Number of subjects: 188
Study 15328774 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Thai passages full of nasal consonants
Number of subjects: 188
Study 10832268 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus block by low interscalenic tract (Group B)
Number of subjects: 43
Study 10832268 — intervention group
Group type: COMPARATOR
Intervention: Brachial plexus block by armpit tract (Group A)
Number of subjects: 43
Study 9104520 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol patient-controlled sedation (PCS) at a dose of 0.3 mg.kg-1, delay = three min (n = 20)
Number of subjects: 40
Study 9104520 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist-administered midazolam-fentanyl sedation (n = 20)
Number of subjects: 40
Study 9104520 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol patient-controlled sedation (PCS)
Number of subjects: 40
Study 8471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (2 mg kg‐1)
Number of subjects: 25
Study 8471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (2.5 and 3 mg kg‐1)
Number of subjects: 25
Study 8471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (4.5 and 6 mg kg‐1)
Number of subjects: 25
Study 8471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (all doses)
Number of subjects: 25
Study 3524531 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (450 micrograms/day)
Number of subjects: 147
Study 3524531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 31448793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonotherapy
Number of subjects: 80
Study 31448793 — intervention group
Group type: COMPARATOR
Intervention: Control (no sonotherapy)
Number of subjects: 80
Study 29865929 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel pressure (inspiratory positive airway pressure: 12 cm H2O; expiratory positive airway pressure: 8 cm H2O)
Number of subjects: 68
Study 29865929 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (8 cm H2O)
Number of subjects: 68
Study 29865929 — intervention group
Group type: COMPARATOR
Intervention: Respiratory muscle training (RMT)
Number of subjects: 68
Study 26861608 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg per day) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for a total of six cycles
Number of subjects: 30
Study 26861608 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus CHOP
Number of subjects: 30
Study 24503413 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/high GI dietary group
Number of subjects: 191
Study 24503413 — intervention group
Group type: COMPARATOR
Intervention: Low protein/high GI dietary group
Number of subjects: 191
Study 24503413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 191
Study 21806467 — intervention group
Group type: EXPERIMENTAL
Intervention: Protraction Face Mask (PFM) therapy
Number of subjects: 32
Study 21806467 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Twin-Block (RTB) therapy
Number of subjects: 32
Study 21806467 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 32
Study 21244738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxymetazoline (0.05% OMZ, 45 μL containing 22.5 μg of OMZ hydrochloride)
Number of subjects: 72
Study 21244738 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (PSS)
Number of subjects: 72
Study 21244738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxymetazoline (0.05% OMZ)
Number of subjects: 72
Study 21244738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OMZ and PSS)
Number of subjects: 72
Study 18051825 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenges (DBPCFC)
Number of subjects: 304
Study 18051825 — intervention group
Group type: COMPARATOR
Intervention: Skin prick tests with food allergens
Number of subjects: 304
Study 18051825 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire data
Number of subjects: 304
Study 18051825 — intervention group
Group type: COMPARATOR
Intervention: Specific IgE determination (Unicap 100)
Number of subjects: 304
Study 18051825 — intervention group
Group type: COMPARATOR
Intervention: Food challenges
Number of subjects: 304
Study 16164886 — intervention group
Group type: COMPARATOR
Intervention: Xenadrine EFX
Number of subjects: 10
Study 16164886 — intervention group
Group type: COMPARATOR
Intervention: Advantra Z
Number of subjects: 10
Study 12131352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical morphine (0.04 mg/kg/hour)
Number of subjects: 80
Study 12131352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study 10069634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh repair
Number of subjects: 200
Study 10069634 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 200
Study 7733029 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic clamping
Number of subjects: 9
Study 7733029 — intervention group
Group type: COMPARATOR
Intervention: Without clamping
Number of subjects: 9
Study 2383364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% CHP cream
Number of subjects: 29
Study 2383364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% CHP cream
Number of subjects: 29
Study 2383364 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulphadiazine (AgSD) cream
Number of subjects: 29
Study 2383364 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHP cream
Number of subjects: 29
Study 2383364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle (control for CHP)
Number of subjects: 29
Study 7219904 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antihypertensive agents (placebo, hydralazine, or methyldopa)
Number of subjects: 63
Study 7219904 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized group (high-risk pregnancy clinics)
Number of subjects: 63
Study 30667500 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sibling donor hematopoietic stem cell transplantation (MSD‐HSCT) (n=32)
Number of subjects: 67
Study 30667500 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=35)
Number of subjects: 67
Study 28109057 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMA stent
Number of subjects: 732
Study 28109057 — intervention group
Group type: COMPARATOR
Intervention: Excel SES
Number of subjects: 732
Study 25643050 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg once daily) administered on days 11-14 with erlotinib (150 mg) on day 15
Number of subjects: 24
Study 25643050 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg once daily) administered in the morning for 5 days, 2 h before erlotinib (150 mg)
Number of subjects: 24
Study 25643050 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily) administered for 5 days, with staggered dosing of erlotinib (150 mg)
Number of subjects: 24
Study 25643050 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 24
Study 25184863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and dexamethasone until disease progression (535 patients)
Number of subjects: 1623
Study 25184863 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 cycles of lenalidomide and dexamethasone (541 patients)
Number of subjects: 1623
Study 25184863 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisone-thalidomide (MPT) for 72 weeks (547 patients)
Number of subjects: 1623
Study 25184863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and dexamethasone
Number of subjects: 1623
Study 25184863 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 cycles of lenalidomide and dexamethasone
Number of subjects: 1623
Study 25184863 — intervention group
Group type: COMPARATOR
Intervention: MPT
Number of subjects: 1623
Study 21880545 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented low-Dye taping
Number of subjects: 27
Study 21880545 — intervention group
Group type: EXPERIMENTAL
Intervention: Replaceable ankle brace
Number of subjects: 27
Study 21880545 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 27
Study 20220184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (400 microg/kg)
Number of subjects: 812
Study 20220184 — intervention group
Group type: COMPARATOR
Intervention: 0.5% malathion lotion
Number of subjects: 812
Study 17600607 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (20 mg/day and 30 mg/day)
Number of subjects: 110
Study 17600607 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110
Study 17600607 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 110
Study 15992412 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 15992412 — intervention group
Group type: COMPARATOR
Intervention: TXA
Number of subjects: 0
Study 15992412 — intervention group
Group type: COMPARATOR
Intervention: EACA
Number of subjects: 0
Study 12004990 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (0.05, 0.1, 0.2, and 0.3 microg x k(‐1) x min(‐1))
Number of subjects: 37
Study 12004990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 37
Study 12004990 — intervention group
Group type: COMPARATOR
Intervention: High-dose epinephrine
Number of subjects: 37
Study 12004990 — intervention group
Group type: COMPARATOR
Intervention: Baseline QTc
Number of subjects: 37
Study 12004990 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-induced nonsustained ventricular tachycardia
Number of subjects: 37
Study 10661631 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 159
Study 10661631 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (SP) solution
Number of subjects: 159
Study 10661631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 159
Study 7788955 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg) administered intravenously over 10 min
Number of subjects: 18
Study 7788955 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no intervention)
Number of subjects: 18
Study 2365041 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline nebulized twice daily for 2 + 2 weeks
Number of subjects: 48
Study 2365041 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulized twice daily for 2 + 2 weeks
Number of subjects: 48
Study 6802260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 2 months
Number of subjects: 194
Study 6802260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 5 months
Number of subjects: 194
Study 6802260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 31342560 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 62
Study 29158664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (NGTS) administered for 24 weeks, with a possible uptitration to 60 mg/d after 4 weeks if BP reduction was unsatisfactory.
Number of subjects: 138
Study 26089304 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing
Number of subjects: 258
Study 26089304 — intervention group
Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 258
Study 26280719 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 112
Study 26280719 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 112
Study 22251291 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal action experience via Velcro sticky mittens
Number of subjects: 2
Study 22251291 — intervention group
Group type: COMPARATOR
Intervention: Non-causal action experience via non-sticky mittens
Number of subjects: 2
Study 19465142 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 30
Study 19465142 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 30
Study 19465142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19771959 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression augmented with a p‐GlcNAc fiber‐based hemostatic dressing
Number of subjects: 20
Study 19771959 — intervention group
Group type: COMPARATOR
Intervention: Manual compression alone
Number of subjects: 20
Study 15875127 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg x kg(‐1) propofol
Number of subjects: 80
Study 15875127 — intervention group
Group type: COMPARATOR
Intervention: Tidal breath desflurane
Number of subjects: 80
Study 12825997 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% twice daily (TD)
Number of subjects: 84
Study 12825997 — intervention group
Group type: COMPARATOR
Intervention: Flutrimazole 1% once daily (OD)
Number of subjects: 84
Study 9460336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg/m2 i.v., day 1), 5‐fluorouracil (350 mg/m2 i.v. days 1‐3), leucovorin (300 mg i.v. days 1‐3)
Number of subjects: 128
Study 9460336 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2 i.v. 1‐h infusion) added to NFL regimen
Number of subjects: 128
Study 9460336 — intervention group
Group type: COMPARATOR
Intervention: CMF regimen (cyclophosphamide 600 mg/m2 i.v. day 1, methotrexate 40 mg/m2 day 1; 5FU 600 mg/m2 i.v. day 1)
Number of subjects: 128
Study 8203993 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef (85 g of cooked beef, 8% fat)
Number of subjects: 38
Study 8203993 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken (85 g of cooked chicken, 7% fat)
Number of subjects: 38
Study 8203993 — intervention group
Group type: COMPARATOR
Intervention: Beef and Chicken
Number of subjects: 38